DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes.
DiaPep277 is an immunomodulatory peptide that arrests beta cell destruction in mouse models of type 1 diabetes mellitus (T1DM). This article extends an original pilot observation to two studies of 61 patients (age > 16 years), diagnosed with T1DM within 6 months, and with measurable beta cell function. Patients were treated with placebo (n = 27) or 1.0 mg DiaPep277 (n = 34). After 13 months, 1.0 mg Dia Pep277 treatment significantly (P = 0.02) preserved beta cell function as compared to the control with a trend for reduced HbA1c. This was achieved without an increase in insulin dose in the DiaPep277 group and with excellent safety. DiaPep277-treated patients also had fewer Th1 DiaPep277-specific T cells.
Elias
Dana
D
DeveloGen Israel Ltd., Kiryat Weizmann, Rehovot 76326, Israel. Elias@Develogen.com
Avron
Ann
A
Tamir
Merana
M
Raz
Itamar
I
D000595:Amino Acid Sequence; D019540:Area Under Curve; D002096:C-Peptide / Q000097:blood; D018834:Chaperonin 60; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000378:metabolism*; D007328:Insulin / Q000096:biosynthesis*; D050417:Insulin-Secreting Cells / Q000378:metabolism; D008297:Male; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D010455:Peptides / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D002096:C-Peptide; D018834:Chaperonin 60; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D010446:Peptide Fragments; D010455:Peptides; C447781:DiaPep 277